About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Success in AIDS Fight in Brazil Linked to Cheap Drugs

by Rajashri on July 31, 2008 at 2:13 PM
Font : A-A+

 Success in AIDS Fight in Brazil Linked to Cheap Drugs

Cheap retroviral treatments secured from the big drug companies is the key to Brazil's success in fighting AIDS.

That fight goes on today, with Brazil also manufacturing its own generic anti-AIDS medicine.

Advertisement

The strategy has created friction with the pharmaceutical groups investing billions in new anti-virals -- but it has also proved successful in this vast country, population 190 million, which has a third of Latin America's HIV-positive patients.

Around 32,000 new HIV/AIDS carriers are detected every year, a proportion that has stayed roughly the same for the past two decades.

That in itself is a triumph for a nation which was once predicted to be on the same path as parts of Africa where AIDS transmission has exploded, creating a veritable crisis.
Advertisement

The director of the Brazilian health ministry's AIDS program, Mariangela Simao, told AFP that in 2002, the prevelance rate of HIV/AIDS per 100,000 people was 22.2 cases. In 2006, it was 17.5, "which confirms a slightly lower trend," she said.

The government, though, is determined to push back further against the disease, said Simao, who will be attending an international AIDS conference in Mexico next week.

There are currently 620,000 people with HIV living in Brazil, or 0.61 percent of the population between 15 and 49. Of those, 190,000 with AIDS receive free treatment.

The health ministry spent 820 million dollars last year on its AIDS program, of which 620 million dollars went to paying for retroviral medicine.

"Each year, 18,000 to 20,000 people are being treated for AIDS," Simao said, adding that Brazil has made 16 types of retroviral treatments available.

Seven of those treatments are non-patented generics made in Brazil by state laboratories.

The other nine are imported at prices negotiated every year by Brazil to fulfil its promise of providing universal access to the drugs.

Last year, Brazil failed to secure a deal with the US pharmaceutical Merck for the HIV retroviral efavirenz.

It decided to break the patent on the drug -- the first time it has done so -- and is importing it from India pending its own generic production.

The 30 million dollars per year it is saving by doing so is being reinvested in HIV prevention.

"Between our trade and our health, we have chosen to look after our health," President Luiz Inacio Lula da Silva said at the time.

Simao explained that 80,000 patients with HIV in Brazil were receiving efavirenz, and two Brazilian laboratories were developing the drug. "It should be for sale on our market in 2009," she said.

The official said the government was well-placed to buy other treatments for the one-third of AIDS patients who were in a more advanced stage of the disease.

"The government buys in bulk, so it has a good margin for negotiation," she said.

"But that's not the case for countries like Chile or Mexico, which are paying five to seven times more because they are reliant on trade accords with the United States," she noted.

At the AIDS conference, "Brazil and France will steer the discussion towards the fact that it is possible to achieve universal access for these medicines by 2010, and will look at the impact on patents this access would have," she said.

Source: AFP
RAS/L
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Pepper as Preventive Measure Against Omicron
FODMAP Diet: A Beginner's Guide
Smallpox
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs AIDS - Initial Theories and Disease Progression 

Recommended Reading
AIDS/HIV - Epidemiology
AIDS or HIV is an epidemic disease, a potentially deadly infection that can be prevented with ......
Female Condom - Animation
Animation on how to use Female condom and its advantages....
How to use a condom - Animation
This Interactive provides step by step visual aid showing how to correctly use condoms which can ......
US Triples Fund for Poorest Countries to Fight AIDS, Malaria, TB
US President George W. Bush on Wednesday signed legislation tripling funds to fight the killer ......
AIDS - Initial Theories and Disease Progression
AIDS was first detected in early 1980s, among gays, Haitians and black Africans. HIV is a descendant...
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV...
AIDS/HIV
"AIDS is an epidemic disease, a potentially preventable, deadly infection for which there is no cure...
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features...
AIDS/HIV - Health Education
Encyclopedia section of medindia gives general info about AIDS information and health education....
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Oral Health And AIDS
AIDS has taken on massive proportions in modern times. It is estimated that over 15 million people a...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use